Clinical trials: Acute Ischemia
Stroke, Acute Ischemic Stroke
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
This study is a multi-center, multi-phase, multi-cohort, prospective, randomized, open, blinded endpoint (PROBE), non-significant risk (NSR) device study including up to 420 evaluable subjects measured with the study device(s)…
- Trial name
- VOICE (NCT05547412)
- Testing
- NovaGuide 2 Intelligent Ultrasound System
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NeuraSignal Inc dba NovaSignal
Acute Coronary Syndrome
Multicentre Retrospective Study to Understand Anti-thrombotic Treatment Patterns and Outcomes of Acute Coronary Syndrome (ACS) Patients
TRACE is a Multicentre Retrospective Study planned to gather follow up data for a period of 1 year in order to understand anti-thrombotic management patterns and outcomes of Acute Coronary Syndrome patients in India.
- Trial name
- TRACE (NCT01280630)
- Where
- 7 sites in India
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Acute Ischemic Stroke, Ischemic Stroke
Zeit Alert for Stroke at Home (ZASH) Protocol
This is a single-arm, observational, feasibility study to evaluate if the Halo Alert System can be used in the future to detect stroke events in individuals at risk for stroke wearing the Halo Alert System overnight.
- Conditions
- Acute Ischemic Stroke, Ischemic Stroke, Stroke
- Trial name
- ZASH (NCT05669456)
- Testing
- Halo Alert System
- Volunteers
- 300 people
- Sponsor
- Zeit Medical, Inc.
Acute Myocardial Infarction, Myocardial Viability
The Assessment Of Myocardial Viability Based On CTA/MRI Hybrid Models
The aim of HYBRIDHEART study is to develop new imagistic prototype for a complex evaluation of the myocardial viability by superposing computed tomographic angiographic polar maps of the myocardium with magnetic resonance imaging…
- Conditions
- Acute Myocardial Infarction, Myocardial Viability, Vulnerable Coronary Plaques, Coronary Stenosis
- Trial name
- HYBRIDHEART (NCT04397198)
- Testing
- Speckle Tracking echocardiography
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Coronary Disease
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual…
- Trial name
- NCT00621855
- Testing
- dabigatran etexilate
- Where
- 167 sites in United States, Belgium and 22 more
- Volunteers
- 1,878 people
- Sponsor
- Boehringer Ingelheim
Stroke
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3-9 hours from onset of stroke symptoms.
- Trial name
- DIAS-3 (NCT00790920)
- Testing
- Desmoteplase
- Where
- 102 sites in Australia, Austria and 15 more
- Volunteers
- 492 people
- Sponsor
- H. Lundbeck A/S
Cerebrovascular Accident
A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke
The primary objective of this study is to compare the efficacy of ONO-2506 versus placebo in neurological stroke outcome in patients with acute ischemic stroke.
- Trial name
- NCT00046761
- Testing
- ONO-2506
- Where
- 148 sites in United States, Canada
- Volunteers
- 1,320 people
- Sponsor
- Ono Pharma USA Inc
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
Angina Exacerbation Acute
Effects of Low Frequency Magnetic Field on Exercise Induced Angina
The investigators have previously shown that a frequency of 15.95-16.00 Hz protects against acute myocardial infarction in rats.
- Trial name
- NCT01423422
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Aerotel Ltd
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Myocardial Infarction, Coronary Disease
A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI).
- Trial name
- NCT00060554
- Testing
- fondaparinux sodium, heparin, percutaneous coronary intervention (PCI)
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 300 people
- Sponsor
- Schering-Plough
Cerebrovascular Accident
EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
German stroke units are hesitating to use Aggrenox for secondary ischaemic stroke / transient ischaemic attack (TIA) prevention in a sub-acute treatment setting.
- Trial name
- NCT00562588
- Testing
- Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg), ASA 100 mg qd
- Where
- Germany
- Volunteers
- 551 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
Single-chain urokinase-type plasminogen activator (pro-urokinase) is a highly effective thrombolytic drug. At pharmacologic concentrations however, pro-urokinase is converted to urokinase - a non specific thrombolytic, limiting…
- Trial name
- NCT01694381
- Testing
- M5, C1-inhibitor
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- TSI, LLC
Stroke
Validation of an Electroencephalograph Based Algorithm for Detection of Onset and Deterioration of Acute Ischemic Stroke by Comparison to NIHSS
The purpose of this study is the validation of an Electroencephalograph based algorithm for detection of onset and deterioration of Acute Ischemic Stroke by Comparison to NIHSS.
- Trial name
- NCT01738412
- Testing
- Neurokeeper stroke detector
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Neurokeeper Technologies
Stroke
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke
- Trial name
- NCT02930837
- Testing
- alteplase
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Acute Coronary Syndrome
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).
- Trial name
- NCT00677053
- Testing
- TAK-442
- Where
- 103 sites in United States, Argentina and 17 more
- Volunteers
- 2,753 people
- Sponsor
- Takeda
Sickle Cell Disease
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
To evaluate the relative bioavailability of ticagrelor for the different formulations. A randomized cross-over design has been chosen to minimize the effects of between-subject variability and any period effects on the overall…
- Trial name
- NCT03126695
- Testing
- Ticagrelor granule, Ticagrelor pediatric tablets, Ticagrelor pediatric tablets suspended in water
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Stroke
Desmoteplase in Acute Ischemic Stroke (DIAS)
The DIAS study (Part 2) was performed to support the dose finding of desmoteplase treatment in subjects with acute ischemic stroke selected by perfusion/diffusion mismatch on MRI within a time window of 3 to 9 h after…
- Trial name
- NCT00638781
- Testing
- Desmoteplase
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- PAION Deutschland GmbH
Acute Coronary Syndrome
Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina
The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.
- Trial name
- NCT00353067
- Testing
- veliflapon (DG-031)
- Where
- 11 sites in United States
- Volunteers
- 3,450 people
- Sponsor
- deCODE genetics
Acute Coronary Syndrome
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE-2 (NCT05918861)
- Testing
- Dalcetrapib
- Where
- 231 sites in United States, Canada and 1 more
- Volunteers
- 2,000 people
- Sponsor
- DalCor Pharmaceuticals